Lipella Pharmaceuticals (NASDAQ:LIPO) Issues Quarterly Earnings Results

Lipella Pharmaceuticals (NASDAQ:LIPO) posted its earnings results on Thursday. The company reported ($1.19) earnings per share for the quarter, Zacks reports. Lipella Pharmaceuticals had a negative return on equity of 192.33% and a negative net margin of 882.82%. The firm had revenue of $0.17 million for the quarter.

Lipella Pharmaceuticals Stock Down 4.8 %

Shares of Lipella Pharmaceuticals stock opened at $2.59 on Friday. The company has a 50-day simple moving average of $2.89 and a two-hundred day simple moving average of $3.03. Lipella Pharmaceuticals has a twelve month low of $2.02 and a twelve month high of $12.00. The stock has a market capitalization of $3.13 million, a price-to-earnings ratio of -0.61 and a beta of 0.13.

Lipella Pharmaceuticals Company Profile

Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).